FREQUENCY OF THE SLCO1B1*5 GENE IN RUSSIAN PATIENTS WITH HYPERLIPIDEMIA, RECEIVING STATINS VS. THOSE NOT RECEIVING STATINS

G.N. Shuev (1), D.A. Sychev (2), A.A. Khokhlov (3), A.V. Grachev (4), T.A. Beloshitskaya (4)
1 -I.M.Sechenov First Moscow State Medical University, Russian Federation, 119991, Moscow, Trubetskaya Str., 8;
2 -Russian Medical Academy of Postgraduate Education, Russian Federation 123995, Moscow, Barrikadnaya, 2/1;
3 -Yaroslavl State Medical Academy, Russian Federation, 150000, Yaroslavskaya oblast’, Yaroslavl’, Revolyutscionnaya Str., 5;
4 -SM-clinic, Russian Federation, 125130, Moscow, Klary Tsetkin Str., 33/28

Introduction.SLCO1B1 encodes the organic anion–transporting polypeptide which has been shown to regulate the hepatic uptake of statins. SLCO1B1*5 genetic variant is associated with statin-induced myopathy. The aim of the study. Aim of the study is to research the prevalence of the SLCO1B1*5 genetic variant in the Russian population and to estimate myo-and hepatotoxic effects of statins. Methods.A total of 572 individuals suffered from hyperlipidemia were included in the study. 86 patients received statins and 486 patients did not receive statins. We determined SLCO1B1*5 genetic variant (с.521Т>С, rs4149056) in the each patient by virtue of RealTime PCR. We compared the levels of ALT, AST, and CPK according to the genotype (TT, TC, CC). Results.The prevalence of the SLCO1B1*5 genetic variant in the Russian population can be considered as follows: genotype TT-61%, TC-32,5%, CC-6,5% of patients, n=572. AST levels were higher in the TT genotype (27±14,6) compared with TC carriers (22,6±7) in patients receiving statins, p=0,009. CPK amount was lower in TC genotype patients receiving statins (104±61,6), as compared with the nonreceiving ones (181,1±156,7) p=0,0073. Conclusions. The results show the high occurrence of C allele of SLCO1B1 gene in the Russian population. We should expect a high risk of myopathy in cases receiving statins. AST levels did not exceed normal levels, changes in CPK levels indicate to the toxic effect of statins in carriers of the SLCO1B1 gene C-allele.
Keywords: 
hydroxymethylglutaryl-CoA Reductase Inhibitors, pharmacogenetics, myopathy, the SLCO1B1*5 genetic variant